TY - JOUR
T1 - Time course of vascular structural changes during and after short-term antihypertensive treatment
AU - Hale, Taben M.
AU - Shoichet, Martin J.
AU - Bushfield, Terri L.
AU - Adams, Michael A.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - The present study characterized the persistent changes (ie, off-treatment) resulting from short-term antihypertensive treatments on mean arterial pressure (MAP) and structurally based vascular resistance. Rats were treated for 14 days with enalapril (30 mg · kg-1 · d-1) with regular (ENAL, 0.4%) or low salt (ELS, 0.04%) diets, or a triple therapy (Triple: hydralazine 45 mg · kg-1 · d-1, hydrochlorothiazide 100 mg/L, and nifedipine 200 mg/d). MAP was continuously recorded via radiotelemetry. Structurally based hindlimb vascular resistance properties (resistance at maximum dilation [Max Dil]; resistance at maximum constriction [Max Con]) were assessed after 14-day enalapril treatment and 2 to 3 weeks after all drugs were withdrawn. Aortic urokinase plasminogen activator (uPA) activity was measured by zymography after 14 days of ELS. All treatments induced a significant, persistent decrease in the off-treatment MAP (ENAL ↓ 12±4.6%, ELS ↓16±2.6%, Triple ↓ 5±4.17%). During treatment (14 days) the enalapril group had significant changes in the index of medial bulk (Max Con ↓ 15±2.6%), but only minimal changes in lumen properties (Max Dil ↓ 3±6.5%, NS). After stopping therapy, vascular properties at Max Dil were significantly decreased only in the 2 enalapril groups (ENAL ↓ 15±7.9%, P < 0.05; ELS ↓ 9±6.0%, P < 0.05; Triple ↓ 2±9.8%, NS), whereas Max Con was significantly decreased in all groups (ENAL ↓ 12±8.0%, ELS ↓ 16±6.1%, Triple ↓ 7±5.4%). At 14 days of ELS treatment, there was increased aortic uPA activity (1.6-fold). The findings reveal that various short-term antihypertensive treatments can produce persistent long-term changes in MAP and vascular structure. Further, the magnitude of the depressor response may be as important in inducing persistent changes as is the removal of angiotensin II.
AB - The present study characterized the persistent changes (ie, off-treatment) resulting from short-term antihypertensive treatments on mean arterial pressure (MAP) and structurally based vascular resistance. Rats were treated for 14 days with enalapril (30 mg · kg-1 · d-1) with regular (ENAL, 0.4%) or low salt (ELS, 0.04%) diets, or a triple therapy (Triple: hydralazine 45 mg · kg-1 · d-1, hydrochlorothiazide 100 mg/L, and nifedipine 200 mg/d). MAP was continuously recorded via radiotelemetry. Structurally based hindlimb vascular resistance properties (resistance at maximum dilation [Max Dil]; resistance at maximum constriction [Max Con]) were assessed after 14-day enalapril treatment and 2 to 3 weeks after all drugs were withdrawn. Aortic urokinase plasminogen activator (uPA) activity was measured by zymography after 14 days of ELS. All treatments induced a significant, persistent decrease in the off-treatment MAP (ENAL ↓ 12±4.6%, ELS ↓16±2.6%, Triple ↓ 5±4.17%). During treatment (14 days) the enalapril group had significant changes in the index of medial bulk (Max Con ↓ 15±2.6%), but only minimal changes in lumen properties (Max Dil ↓ 3±6.5%, NS). After stopping therapy, vascular properties at Max Dil were significantly decreased only in the 2 enalapril groups (ENAL ↓ 15±7.9%, P < 0.05; ELS ↓ 9±6.0%, P < 0.05; Triple ↓ 2±9.8%, NS), whereas Max Con was significantly decreased in all groups (ENAL ↓ 12±8.0%, ELS ↓ 16±6.1%, Triple ↓ 7±5.4%). At 14 days of ELS treatment, there was increased aortic uPA activity (1.6-fold). The findings reveal that various short-term antihypertensive treatments can produce persistent long-term changes in MAP and vascular structure. Further, the magnitude of the depressor response may be as important in inducing persistent changes as is the removal of angiotensin II.
KW - Antihypertensive agents
KW - Arterial pressure
KW - Hypertension, experimental
KW - Rats, inbred SHR
KW - Sodium, dietary
KW - Vascular resistance
UR - http://www.scopus.com/inward/record.url?scp=0043268712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0043268712&partnerID=8YFLogxK
U2 - 10.1161/01.HYP.0000079309.68998.65
DO - 10.1161/01.HYP.0000079309.68998.65
M3 - Article
C2 - 12810756
SN - 0194-911X
VL - 42
SP - 171
EP - 176
JO - Hypertension
JF - Hypertension
IS - 2
ER -